1. Home
  2. CRVS vs RM Comparison

CRVS vs RM Comparison

Compare CRVS & RM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRVS
  • RM
  • Stock Information
  • Founded
  • CRVS 2014
  • RM 1987
  • Country
  • CRVS United States
  • RM United States
  • Employees
  • CRVS N/A
  • RM N/A
  • Industry
  • CRVS Biotechnology: Pharmaceutical Preparations
  • RM Finance: Consumer Services
  • Sector
  • CRVS Health Care
  • RM Finance
  • Exchange
  • CRVS Nasdaq
  • RM Nasdaq
  • Market Cap
  • CRVS 305.4M
  • RM 414.8M
  • IPO Year
  • CRVS 2016
  • RM 2012
  • Fundamental
  • Price
  • CRVS $5.75
  • RM $43.75
  • Analyst Decision
  • CRVS Strong Buy
  • RM Hold
  • Analyst Count
  • CRVS 4
  • RM 2
  • Target Price
  • CRVS $15.00
  • RM $30.00
  • AVG Volume (30 Days)
  • CRVS 518.7K
  • RM 52.0K
  • Earning Date
  • CRVS 08-07-2025
  • RM 07-30-2025
  • Dividend Yield
  • CRVS N/A
  • RM 2.74%
  • EPS Growth
  • CRVS N/A
  • RM 35.30
  • EPS
  • CRVS N/A
  • RM 3.47
  • Revenue
  • CRVS N/A
  • RM $591,436,000.00
  • Revenue This Year
  • CRVS N/A
  • RM $16.20
  • Revenue Next Year
  • CRVS N/A
  • RM $7.43
  • P/E Ratio
  • CRVS N/A
  • RM $12.63
  • Revenue Growth
  • CRVS N/A
  • RM 7.19
  • 52 Week Low
  • CRVS $2.54
  • RM $25.41
  • 52 Week High
  • CRVS $10.00
  • RM $43.91
  • Technical
  • Relative Strength Index (RSI)
  • CRVS 65.10
  • RM 82.31
  • Support Level
  • CRVS $5.28
  • RM $36.88
  • Resistance Level
  • CRVS $5.64
  • RM $42.05
  • Average True Range (ATR)
  • CRVS 0.30
  • RM 1.29
  • MACD
  • CRVS 0.03
  • RM 0.49
  • Stochastic Oscillator
  • CRVS 77.70
  • RM 98.79

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

About RM Regional Management Corp.

Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.

Share on Social Networks: